GeneDx Holdings Corp.
Financials
Valuation Metrics
GeneDx Holdings Corp.'s Market Cap is $3.12B. At end of 2025 it was $3.50B. Ranked #1704 of 3,121 in US market (top 55%), #609 of 1,463 on NASDAQ (top 42%), #101 of 205 in Health Care Equipment & Services (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.12B | US#1,704/3,121 Sec#101/205 |
| Revenue | $454M | US#2,305/3,121 Sec#144/205 |
| Net Income | $-106M | US—/3,121 Sec—/205 |
| Total Assets | $481M | US#2,782/3,121 Sec#159/205 |
| Net Assets | $244M | US#2,614/3,121 Sec#154/205 |
| Employees | 1,300 | US#1,893/3,121 Sec#126/205 |
| Value | ||
| P/B | 12.76x | US#2,694/3,121 Sec#174/205 |
| P/S | 6.86x | US#2,527/3,121 Sec#166/205 |
| FCF Yield | -2.43% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -43.55% | US#2,650/3,121 Sec#166/205 |
| ROA | -22.09% | US#2,819/3,121 Sec#180/205 |
| Op. Margin | -13.34% | US#2,570/3,121 Sec#161/205 |
| Revenue Growth | 25.42% | US#525/3,121 Sec#31/205 |
| Earnings Growth | -7664.51% | US#2,049/3,121 Sec#105/205 |
| Financial Health | ||
| Debt Ratio | 97.15% | US#1,073/3,121 Sec#101/205 |
| Total Debt | $167M | US#2,302/3,121 Sec#128/205 |
| FCF | $-76M | US#2,587/3,121 Sec#185/205 |
| Cash | $60M | US#2,502/3,121 Sec#158/205 |
| Current Ratio | 3.30x | US#707/3,121 Sec#71/205 |
| Performance | ||
| 1Y Return | -17.96% | US#2,351/3,121 Sec#160/205 |
| 1M Return | 37.48% | US#25/3,121 Sec#6/205 |
| From 52W High | -38.58% | US#2,422/3,121 Sec#161/205 |
| 1Y MDD | -79.40% | US#3,065/3,121 Sec#198/205 |
| Trading | ||
| Volume | 793,435 shares | US#1,606/3,121 Sec#101/205 |
| Trading Value | $82M | US#953/3,121 Sec#74/205 |
| Per Share | ||
| EPS | $-3.58 | US—/3,121 Sec—/205 |
| BPS | $8.23 | US#1,980/3,121 Sec#115/205 |
Company Info
GeneDx Holdings Corp. functions as a health intelligence firm singularly focused on the individual patient. It aims to revolutionize healthcare delivery by deploying advanced artificial intelligence and machine learning capabilities. These sophisticated algorithms are applied to vast, longitudinal clinical and genomic datasets to construct comprehensive, dynamic models of human health, ultimately defining personalized, optimal pathways for each person's well-being. Through its exclusive Centrellis health intelligence platform, the company gains profound insights into both disease states and overall wellness, enabling it to furnish evidence-based solutions for the most critical medical challenges. Eric Schadt established the corporation in October 2015, and its principal offices are located in Stamford, Connecticut.